Pharma, IT sectors will face biggest risk from US protectionist moves: Nomura

India’s pharmaceutical and IT services companies will face the biggest risk from US protectionist moves, says Nomura.

Washington had launched a challenge against Indian export subsidies at the World Trade Organization last month, saying they hurt US companies by letting Indian exporters sell goods more cheaply.

About 78 per cent of India’s exports benefit from export promotion schemes; any measure to curb incentives will have adverse impact on India’s export competitiveness, it says.

Protectionist moves by US can directly impact sectors such as IT services, pharmaceuticals, textiles and precious metals. Pharmaceutical sector, which is largely dependent on exports, will be adversely impacted as export incentives are material contributor to profitability, according to Nomura.

Although Indian IT services have not benefited materially from incentive schemes, they face headwinds from tighter US immigration laws, which can hit their margins. Impact is likely to be lower for other exporting sectors such as autos and engineering goods, Nomura adds.

PHARMALEADERS

Pharmaleaders is India’s first opinion based & research driven bi-monthly magazine & has a decade of relentless reporting in Pharma Journalism in an unbiased, fearless & independent way. Over the last one decade, The Magazine has covered some of the biggest voices in the healthcare Industry. Available both in digital & printed format, Pharmaleaders has emerged out as a leading title in voicing the opinion of the healthcare industry.